New pill aims to tackle high blood pressure in overweight patients

NCT ID NCT07528027

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether the drug HRS-7535 can lower blood pressure better than a placebo in 648 adults with hypertension who are also overweight or obese. Participants will take the drug or placebo for up to 48 weeks, and researchers will measure changes in blood pressure and weight. The goal is to find a new treatment option for this common combination of health issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7535
What this could lead to: If it works, this could offer a new treatment option for people with high blood pressure who are also overweight or obese.
What could go wrong: This is still an experimental drug. Even in Phase 3, it may not prove better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION WITH OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
The First Affiliated Hospital of Harbin Medical University
RECRUITING

Harbin, Heilongjiang, 163711, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.